Genetic analyses reveal differences in the VP7 and VP4 antigenic epitopes between human rotaviruses circulating in Belgium and rotaviruses in rotarix and RotaTeq

Journal of Clinical Microbiology

Volumn 50, Issue 3, 2012, Pages 966-976

  Zeller, Mark ^a   Patton, John T ^b   Heylen, Elisabeth ^a   De Coster, Sarah ^a   Ciarlet, Max ^c   Van Ranst, Marc ^a   Matthijnssens, Jelle ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; LIVE VACCINE; PROTEIN VP4; PROTEIN VP7; ROTA TEQ; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BELGIUM; CHILD; CONTROLLED STUDY; DRUG EFFICACY; EPITOPE MAPPING; FEMALE; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN ROTAVIRUS; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEQUENCE ANALYSIS; SEROTYPE; VIRUS ISOLATION; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; ANTIGENS, VIRAL; BELGIUM; CAPSID PROTEINS; EPIDEMIOLOGIC STUDIES; EPITOPES; HUMANS; MOLECULAR EPIDEMIOLOGY; MUTATION, MISSENSE; RNA, VIRAL; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SEQUENCE ANALYSIS, DNA; VACCINES, ATTENUATED;

EID: 84857438141     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.05590-11     Document Type: Article

References (67)

1. Aoki ST, et al. 2009. Structure of rotavirus outer-layer protein VP7 bound with a neutralizing Fab. Science 324:1444-1447.
2. Arista S, et al. 2006. Heterogeneity and temporal dynamics of evolution of G1 human rotaviruses in a settled population. J. Virol. 80:10724-10733. (Pubitemid 44628918)
3. Ball JM, Tian P, Zeng CQ, Morris AP, Estes MK. 1996. Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein. Science 272:101-104. (Pubitemid 26110759)
4. Banyai K, et al. 2009. Trends in the epidemiology of human G1P[8] rotaviruses: a Hungarian study. J. Infect. Dis. 200(Suppl 1):S222-S227.
5. Boom JA, et al. 2010. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 125:e199-e207.
6. Buttery JP, et al. 2011. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Pediatr. Infect. Dis. J. 30:S25-S29.
7. Ciarlet M, Hoshino Y, Liprandi F. 1997. Single point mutations may affect the serotype reactivity of serotype G11 porcine rotavirus strains: a widening spectrum? J. Virol. 71:8213- 8220.
8. Ciarlet M, Reggeti F, Pina CI, Liprandi F. 1994. Equine rotaviruses with G14 serotype specificity circulate among Venezuelan horses. J. Clin. Microbiol. 32:2609-2612. (Pubitemid 24284679)
9. Ciarlet M, Schodel F. 2009. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq. Vaccine 27(Suppl 6):G72-G81.
10. Clark HF, Lawley D, Mallette LA, DiNubile MJ, Hodinka RL. 2009. Decline in cases of rotavirus gastroenteritis presenting to The Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine. Clin. Vaccine Immunol. 16:382-386.
11. Cunliffe NA, et al. 2001. Rotavirus strain diversity in Blantyre, Malawi, from 1997 to 1999. J. Clin. Microbiol. 39:836-843. (Pubitemid 32209689)
12. Curns AT, et al. 2010. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J. Infect. Dis. 201:1617-1624.
13. de Palma O, et al. 2010. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ 340:c2825.
14. De Vos B, et al. 2009. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials. Pediatr. Infect. Dis. J. 28:261-266.
15. DiStefano DJ, et al. 2005. Novel rotavirus VP7 typing assay using a one-step reverse transcriptase PCR protocol and product sequencing and utility of the assay for epidemiological studies and strain characterization, including serotype subgroup analysis. J. Clin. Microbiol. 43:5876-5880. (Pubitemid 43100632)
16. Dormitzer PR, Nason EB, Prasad BV, Harrison SC. 2004. Structural rearrangements in the membrane penetration protein of a non-enveloped virus. Nature 430:1053-1058. (Pubitemid 39136201)
17. Dormitzer PR, Sun ZY, Wagner G, Harrison SC. 2002. The rhesus rotavirus VP4 sialic acid binding domain has a galectin fold with a novel carbohydrate binding site. EMBO J. 21:885-897. (Pubitemid 34206162)
18. Estes M, Kapikian A. 2007. Rotaviruses, p 1917-1974. In Knipe M, Howley P (ed), Fields virology, 5th ed. Lippincott/Williams & Wilkins, Philadelphia, PA.
19. Goveia MG, Ciarlet M, Owen KE, Ranucci CS. 2011. Development, clinical evaluation, and post-licensure impact of RotaTeq®, a pentavalent rotavirus vaccine. Ann. N. Y. Acad. Sci. 1222:14-18.
20. Heaton PM, Ciarlet M. 2007. Vaccines: the pentavalent rotavirus vaccine: discovery to licensure and beyond. Clin. Infect. Dis. 45:1618-1624. (Pubitemid 351411848)
21. Hoshino Y, et al. 2004. Rotavirus serotype G9 strains belonging to VP7 gene phylogenetic sequence lineage 1 may be more suitable for serotype G9 vaccine candidates than those belonging to lineage 2 or 3. J. Virol. 78:7795-7802.
22. Huang SW, et al. 2009. Reemergence of enterovirus 71 in 2008 in Taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J. Clin. Microbiol. 47:3653-3662.
23. Hull JJ, et al. 2011. United States rotavirus strain surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction. Pediatr. Infect. Dis. J. 30:S42-S47.
24. Jin Q, et al. 1996. Divergence of VP7 genes of G1 rotaviruses isolated from infants vaccinated with reassortant rhesus rotaviruses. Arch. Virol. 141:2057-2076. (Pubitemid 27012270)
25. Khananurak K, et al. 2010. Prevalence and phylogenetic analysis of rotavirus genotypes in Thailand between 2007 and 2009. Infect. Genet. Evol. 10:537-545.
26. Kirkwood CD, Boniface K, Barnes GL, Bishop RF. 2011. Distribution of rotavirus genotypes after introduction of rotavirus vaccines, Rotarix® and RotaTeq®, into the National Immunization Program of Australia. Pediatr. Infect. Dis. J. 30:S48 -S53.
27. Kirkwood CD, Boniface K, Bishop RF, Barnes GL. 2011. Australian Rotavirus Surveillance Program: annual report, 2009/2010. Commun. Dis. Intell. 34:427-434.
28. Lanzieri TM, et al. 2010. Trends in hospitalizations from all-cause gastroenteritis in children younger than 5 years of age in Brazil before and after human rotavirus vaccine introduction, 1998-2007. Pediatr. Infect. Dis. J. 29:673-675.
29. Matthijnssens J, et al. 2009. Rotavirus disease and vaccination: impact on genotype diversity. Future Microbiol. 4:1303-1316.
30. Matthijnssens J, et al. 2008. Full genome-based classification of rotaviruses reveals a common origin between human Wa-Like and porcine rotavirus strains and human DS-1-like and bovine rotavirus strains. J. Virol. 82:3204-3219. (Pubitemid 351429901)
31. Matthijnssens J, et al. 2011. Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG). Arch. Virol. 156:1397-1413.
32. Matthijnssens J, et al. 2008. Recommendations for the classification of group A rotaviruses using all 11 genomic RNA segments. Arch. Virol. 153:1621-1629.
33. Matthijnssens J, et al. 2010. Phylodynamic analyses of rotavirus genotypes G9 and G12 underscore their potential for swift global spread. Mol. Biol. Evol. 27:2431-2436.
34. Matthijnssens J, et al. 2010. Molecular and biological characterization of the 5 human-bovine rotavirus (WC3)-based reassortant strains of the pentavalent rotavirus vaccine, RotaTeq. Virology 403:111-127.
35. Matthijnssens J, Rahman M, Ciarlet M, Van Ranst M. 2008. Emerging human rotavirus genotypes, p 171-219. In Palombo KC (ed), Viruses in the environment. Research Signpost, Trivandrum, India.
36. Matthijnssens J, et al. 2006. Full genomic analysis of human rotavirus strain B4106 and lapine rotavirus strain 30/96 provides evidence for interspecies transmission. J. Virol. 80:3801-3810.
37. McDonald SM, et al. 2009. Evolutionary dynamics of human rotaviruses: balancing reassortment with preferred genome constellations. PLoS Pathog. 5:e1000634.
38. Molto Y, et al. 2011. Reduction of diarrhea-associated hospitalizations among children aged < 5 Years in Panama following the introduction of rotavirus vaccine. Pediatr. Infect. Dis. J. 30:S16-S20.
39. Nagashima S, et al. 2009. Characterization of full-length VP4 genes of OP354-like P[8] human rotavirus strains detected in Bangladesh representing a novel P[8] subtype. Arch. Virol. 154:1223-1231.
40. Nguyen TA, et al. 2008. Use of sequence analysis of the VP4 gene to classify recent Vietnamese rotavirus isolates. Clin. Microbiol. Infect. 14:235-241. (Pubitemid 351201014)
41. Palomo C, Cane PA, Melero JA. 2000. Evaluation of the antibody specificities of human convalescent-phase sera against the attachment (G) protein of human respiratory syncytial virus: influence of strain variation and carbohydrate side chains. J. Med. Virol. 60:468-474. (Pubitemid 30127320)
42. Parashar UD, et al. 2009. Global mortality associated with rotavirus disease among children in 2004. J. Infect. Dis. 200(Suppl 1):S9-S15.
43. Parashar UD, Gibson CJ, Bresse JS, Glass RI. 2006. Rotavirus and severe childhood diarrhea. Emerg. Infect. Dis. 12:304-306.
44. Parra GI, Bok K, Martinez V, Russomando G, Gomez J. 2005. Molecular characterization and genetic variation of the VP7 gene of human rotaviruses isolated in Paraguay. J. Med. Virol. 77:579-586. (Pubitemid 41609600)
45. Patel M, et al. 2009. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 301:2243-2251.
46. Paulke-Korinek M, Rendi-Wagner P, Kundi M, Kronik R, Kollaritsch H. 2009. Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in Austrian children. Pediatr. Infect. Dis. J. 29:319 -323.
47. Pettersen EF, et al. 2004. UCSF Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 25:1605-1612.
48. Phua KB, et al. 2005. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. J. Infect. Dis. 192(Suppl 1):S6-S16. (Pubitemid 41193096)
49. Rahman M, et al. 2007. Evolutionary history and global spread of the emerging g12 human rotaviruses. J. Virol. 81:2382-2390.
50. Richardson S, et al. 1998. Extended excretion of rotavirus after severe diarrhoea in young children. Lancet 351:1844-1848. (Pubitemid 28279708)
51. Ruiz-Palacios GM, et al. 2006. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med. 354:11-22. (Pubitemid 43048947)
52. Samajdar S, et al. 2008. Human group A rotavirus P[8] Hun9-like and rare OP354-like strains are circulating among diarrhoeic children in Eastern India. Arch. Virol. 153:1933-1936.
53. Santos N, Hoshino Y. 2005. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev. Med. Virol. 15:29-56. (Pubitemid 40070041)
54. Skehel JJ, et al. 1984. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc. Natl. Acad. Sci. U. S. A. 81:1779-1783. (Pubitemid 14149547)
55. Smith DJ, et al. 2004. Mapping the antigenic and genetic evolution of influenza virus. Science 305:371-376. (Pubitemid 38938148)
56. Soares-Weiser K, et al. 2010. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst. Rev. 2010:CD008521.
57. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: molecular evolutionary genetics analysis (MEGA) software, version 4.0. Mol. Biol. Evol. 24:1596-1599. (Pubitemid 47236692)
58. Utachee P, et al. 2010. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01-AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain. J. Virol. 84:4311-4320.
59. Vesikari T, Karvonen A, Ferrante SA, Ciarlet M. 2010. Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study. Eur. J. Pediatr. 169:1379-1386.
60. Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet M. 2010. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr. Infect. Dis. J. 29:957-963.
61. Vesikari T, et al. 2007. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 370:1757-1763. (Pubitemid 350137490)
62. Vesikari T, et al. 2006. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. 354:23-33. (Pubitemid 43048948)
63. Ward R. 2009. Mechanisms of protection against rotavirus infection and disease. Pediatr. Infect. Dis. J. 28:S57-S59.
64. Ward RL. 2008. Rotavirus vaccines: how they work or don't work. Expert Rev. Mol. Med. 10:e5.
65. Ward RL, Bernstein DI. 2009. Rotarix: a rotavirus vaccine for the world. Clin. Infect. Dis. 48:222-228.
66. Zeller M, Matthijnssens J, Rahman M, Van Ranst M. 2009. Possible immune evasion by G1 lineage I after vaccine introduction in Belgium? Third European Rotavirus Biology Meeting, Loch Lomond, Scotland.
67. Zeller M, et al. 2010. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine 28:7507-7513.